Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORALLEEN: Ribociclib + Letrozole vs Chemotherapy in Luminal B Breast Cancer
NCT03248427Phase 2Completed
- Sponsor
- SOLTI
- Start
- Jul 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ribociclib in breast cancer (2 arms), sponsored by SOLTI. Primary endpoint: Rate of ROR-low according to the Prosigna test at 24 weeks. Started Jul 2017; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03248427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03248427.